|
|
|
| Effects of Clarithromycin combined with Tiotropium Bromide for the levels of procalcitonin, C reactive protein in elderly patients with acute exacerbation of chronic obstructive pulmonary disease |
| XU Yinghui1 LI Xiang1 XU Dan2 |
1.Department of Respiratory, Fushun Central Hospital, Liaoning Province, Fushun 113006, China;
2.Department of Science and Education, Fushun Central Hospital, Liaoning Province, Fushun 113006, China |
|
|
|
|
Abstract Objective To observe the effects of Clarithromycin combined with Tiotropium Bromide for the levels of procalcitonin, C reactive protein in elderly patients with acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods Sixty elderly patients with acute exacerbation of COPD treated in Fushun Central Hospital of Liaoning Province from October 2014 to January 2015 were selected and randomly divided into observation group and control group, with 30 cases in each group. The control group received Tiotropium Bromide Dry Powder Inhalation, on basis of which, the observation group received Clarithromycin orally. The improvement of levels of procalcitonin, C reactive protein and lung function [forced expiratory volume in the first second (FEV1), the percentage of forced expiratory volume in the first second accounted for forced vital capacity (FEV1/FVC)] and the conditions of side effects of the two groups were observed and compared. Results There were statistically significant differences of effects between groups, time effects and interaction effects of procalcitonin, C reactive protein in the two groups (P ＜ 0.05). After treatment for 10, 20 d, the levels of procalcitonin, C reactive protein in the two groups were all lower than those on admission, which after treatment for 20 d were lower than those after treatment for 10 d, the differences were all statistically significant (P ＜ 0.05). After treatment for 10, 20 d, the levels of procalcitonin, C reactive protein in the observation group were significantly lower than those of control group (P ＜ 0.05). After treatment, the levels of FEV1, FEV1/FVC in the two groups were all higher than those before treatment (P ＜ 0.05), which of observation group was higher than that of control group (P ＜ 0.05). Both groups had no serious adverse reactions. Conclusion Clarithromycin combined with Tiotropium Bromide has significant effects on the levels of procalcitonin and C reactive protein expression in elderly patients with acute exacerbation of COPD, which can improve the pulmonary function of patients, thus it is worthy of promotion and application in clinic.
|
|
|
|
|
|
[1] Szalai Z，Molnár TF，Lorinczy D，et al. Differential scanning calorimetry（DSC）of blood serum in chronic obstructive pulmonary disease（COPD）：A new diagnostic tool ahead? [J]. Journal of Thermal Analysis and Calorimetry，2013， 113（1）：259-264.
[2] 李新玲，吴振国，朱颀峰，等.肺炎衣原体感染与慢性阻塞性肺疾病的相关性研究[J].中华医院感染学杂志，2015， 12（7）：1567-1568，1571.
[3] 崔中光.大剂量地塞米松优化方案治疗ITP及双靶点联合干预的探索[D].济南：山东大学，2014.
[4] 陈东红，李方治，刘朔，等.老年中重度稳定期慢性阻塞性肺疾病患者应用噻托溴铵的疗效与安全性[J].中国老年学杂志，2015，35（17）：4916-4918.
[5] 刘春，邓述恺.克拉霉素对烟雾暴露哮喘小鼠肺组织中组蛋白去乙酰化酶2及糖皮质激素受体α表达的影响[J].中国抗生素杂志，2017，42（2）：154-159.
[6] 柳涛，蔡柏蔷.慢性阻塞性肺疾病诊断，处理和预防全球策略（2011年修订版）介绍[J].中国呼吸与危重监护杂志，2012，11（1）：1-12.
[7] Osadnik CR，Tee VS，Carsonchahhoud KV，et al. Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease [J]. Cochrane Database of Systematic Reviews，2017，7（7）：CD004104.
[8] 陆霓虹，杨蕤，杨继群，等.COPD并肺心病心力衰竭hs-CRP、BNP检测临床意义分析[J].临床肺科杂志，2013， 18（2）：278-279.
[9] 梅春霞，刘娟，徐智，等.APACHEⅡ评分和降钙素原对肺部感染预后的预测作用[J].第三军医大学学报，2014， 36（8）：802-805.
[10] 高莉.降钙素原与C-反应蛋白对鉴别肺部感染病原体价值的探讨[D].郑州：郑州大学，2013.
[11] 刘德义，马胜喜，刘雨婷，等.白细胞及降钙素原在慢性阻塞性肺疾病患者感染的相关性分析[J].中华医院感染学杂志，2014，24（15）：3879-3881.
[12] 徐大林.老年慢性阻塞性肺炎急性加重患者外周血白细胞、中性粒细胞、C反应蛋白及降钙素原的测定及临床意义[J].安徽医药，2015，32（12）：2358-2360.
[13] Li Y，Xie L，Xin S，et al. Values of procalcitonin and C-reactive proteins in the diagnosis and treatment of chronic obstructive pulmonary disease having concomitant bacterial infection [J]. Pak J Med Sci，2017，33（3）：566-569.
[14] 刘新年.克拉霉素联合噻托溴铵治疗COPD的临床分析[J].现代诊断与治疗，2015，21（8）：1764-1765.
[15] 徐永鸿.噻托溴铵治疗慢性阻塞性肺疾病的疗效观察[J].实用心脑肺血管病杂志，2014，17（8）：140-141.
[16] 陈辉，赖连娣，邓宏伟.布地奈德福莫特罗联合噻托溴铵治疗慢性阻塞性肺疾病急性加重期的临床观察[J].现代医院，2017，17（2）：233-235.
[17] 蔡凌峰，王慧贤，林观康，等.痰热清注射液对慢性阻塞性肺疾病模型大鼠气道黏液高分泌的影响?[J].成都医学院学报，2016，11（6）：657-661.
[18] 宋威蓉，初巍巍，王莉，等.无创呼吸机治疗慢性阻塞性肺疾病合并呼吸衰竭的临床观察[J].中国医学创新，2015， （9）：43-45.
[19] Boeck L，Kostikas K，Blasi F，et al. Prognostic assessment in chronic obstructive pulmonary disease using copeptin：A simplified risk index [J]. European Respiratory Journal，2015，46（suppl 59）：PA3346.
[20] 窦维嘉.首选口服大环内酯类药物门诊治疗下呼吸道感染疗效评价[D].温州：温州医科大学，2014.
[21] 刘凌云，曾勉，左万里，等.哮喘-慢性阻塞性肺疾病重叠综合征患者氧化应激水平及抗氧化治疗效果的研究[J].中国医学创新，2016，13（21）：9-13.
[22] 周新锋，夏晓东.舒利迭联合噻托溴铵对稳定期中重度慢性阻塞性肺疾病患者肺功能的影响[J].中国现代医生，2015，53（23）：28-30，33.
[23] 钱建美，吴峰妹，刘长明，等.慢性阻塞性肺疾病急性加重患者血清PCT、CRP、FIB、PA、D-二聚体水平变化及意义[J].山东医药，2013，53（3）：80-81.
[24] 石建邦，吴健卫，徐非洲，等.慢性阻塞性肺疾病急性加重期患者血清降钙素原检测的临床意义[J].中国老年学杂志，2017，37（5）：1178-1180.
[25] 林少芳，尤丽英，梁艳平，等.慢性阻塞性肺疾病急性加重期患者血清降钙素原的水平变化及意义[J].中国老年学杂志，2016，36（14）：3494-3495.
[26] 刘兆云.头孢哌酮钠舒巴坦钠联合吸入布地奈德治疗慢性阻塞性肺疾病急性加重期患者的临床疗效评价[J].中国现代医生，2017，55（2）：98-100. |
|
|
|
